# Source:Dr. John Campbell, URL:https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg, language:en-UK

## 29.2 times protection from vaccination
 - [https://www.youtube.com/watch?v=2vYslhtMbDw](https://www.youtube.com/watch?v=2vYslhtMbDw)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2021-08-26 00:00:00+00:00

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021

https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e5.htm?s_cid=mm7034e5_w

A proportion of fully vaccinated persons will become infected

Los Angeles County Department of Public Health

May 1 to July 25, 2021

Among 43,127 infections

10,895 (25.3%) fully vaccinated

1,431 (3.3%) partially vaccinated

30,801 (71.4%) unvaccinated

Hospitalized / ITU / Ventilated in those infected

Fully vaccinated

3.2%, 0.5% 0.2%

Partially vaccinated

6.2%, 1.0%, 0.3%

Unvaccinated

7.6%, 1.5%, 0.5%

p less than 0.001 for all comparisons

July 25, fully vaccinated versus unvaccinated

Infection rate among unvaccinated, x 4.9

Hospitalization rate in unvaccinated, x 29.2

May testing

Differences in median Ct values by vaccination status

July testing

No differences were detected among specimens from fully vaccinated

These infection and hospitalization rate data indicate that authorized vaccines were protective against SARS-CoV-2 infection and severe COVID-19 during a period when transmission of the Delta variant was increasing

US hospital pressures

https://www.forbes.com/sites/joewalsh/2021/08/19/these-6-states-have-almost-no-icu-beds-left-as-covid-hospitalizations-soar/?sh=ad819756bb58

Nationally, ITU capacity at 78%

one-third with covid (or 22,345)

Alabama, more ICU patients than total beds

Dozens forced to wait for space

Georgia, 94% of statewide ICU beds are full

Florida and Mississippi, 93%

Texas, 92.7%

Kentucky, 90.7%

Louisiana, 89.3%

Missouri 88.9%

Followed by Oklahoma (87.9%), Arkansas (87.4%), Nevada (85.4%), North Carolina (84.8%), 
South Carolina (83.8%), New Mexico (83.6%), Idaho (82.7%) Maine (80.4%)

UK, ONS

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights

W / E 14 August 2021

Antibodies, 94.2%

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyantibodyandvaccinationdatafortheuk/latest

Percentage of the community population that had COVID-19 was: 

1.28% in England (1 in 80 people)

0.77% in Wales (1 in 130 people) 

1.92% in Northern Ireland (1 in 50 people) 

0.49% in Scotland (1 in 200 people) 

An estimated 1.46% of the UK population were experiencing self-reported long COVID 4th in July 2021

945,000 people in private households (1.46%)

4 in 10 were experiencing these symptoms over a year

Symptoms adversely affected the day-to-day activities of around two-thirds

Fatigue, shortness of breath, muscle ache, loss of smell, GI

More common in 

females

those aged 35 to 69 years

people living in the most deprived areas

those working in health or social care

those with another health condition or disability.

4th July to 14th August, percentage of people testing positive daily

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections

Deaths, W/E 13th August

https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/latest

14.1% above the five-year average (1,203 more deaths)

England and Wales, 571 mentioned “novel coronavirus (COVID-19)”

(5.5% of all deaths)

North Korea

Population, 25 million

https://www.washingtonpost.com/world/asia_pacific/north-korea-vaccine-delay/2021/08/24/fdf1b054-031a-11ec-825d-01701f9ded64_story.html

Vaccinations so far, 0

UN now offering doses, Covax 

3 million doses of Sinovac

Technical issues still need to be resolved

Sealed its borders to trade and visitors

Essentially no international staff on the ground

Floods, typhoons, heat wave

Lag in routine vaccination program since 2020

2007 measles vaccine campaign, 3.3 million people per day

## Questions for FDA
 - [https://www.youtube.com/watch?v=WOtvpk9rZLs](https://www.youtube.com/watch?v=WOtvpk9rZLs)
 - RSS feed: https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg
 - date published: 2021-08-25 00:00:00+00:00

Peter Doshi, senior editor, The BMJ

The FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines

https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/

Pfizer press release, 1 April, 2021

https://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-and-BioNTech-Confirm-High-Efficacy-and-No-Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study/default.aspx

BNT162b2 is highly effective with 91.3% vaccine efficacy

Data cut-off date was 13 March

measured seven days through up to six months after the second dose

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine, (Published 28 July)

https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1

Ongoing phase 3 covid-19 vaccine trial

VE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6 months of follow-up, 

The current report provides updated efficacy analyses conducted on cases accrued up to March 13, 2021.

Efficacy, an average decline of ~6% every 2 months

FDA Approves First COVID-19 Vaccine, (23rd August)

https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 202, (Published 18th August)

https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w

(NY data)

Protection against infection

July 25, 79.8%

Age adjusted effectiveness against hospitalizations

July 25, 91.9% to 95.3%

During May 3–July 25, 2021, the overall age-adjusted VE against new COVID-19 cases for all adults declined from 91.7% to 79.8%. 

During the same period, the overall age-adjusted VE against hospitalization was relatively stable, ranging from 91.9% to 95.3%.

Israel sees drop in Pfizer vaccine protection against infections

https://www.reuters.com/world/middle-east/israel-sees-drop-pfizer-vaccine-protection-against-infections-still-strong-2021-07-05/

Vaccine effectiveness in preventing both infection and symptomatic disease fell to 64% since June 6

Israel says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness

https://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html

Data from June 20 and July 17

Pfizer sales

https://www.bmj.com/content/374/bmj.n2096

https://www.fiercepharma.com/pharma/pfizer-now-expects-covid-19-vaccine-sales-33-5b-a-7-5b-increase-from-3-months-ago

The company now predicts 2021 sales of $33.5 billion

Pfizer and BioNTech now expect to deliver 2.1 billion doses of Comirnaty worldwide this year and manufacture 3 billion. 

(at average price of $15.95)

2022 production capacity at 4 billion doses

